On the contrary, the expression level of YTHDC2 was notably down‐regulated in ACC, bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), CESC, colon adenocarcinoma (COAD), oesophageal carcinoma (ESCA), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), LUSC, OV, prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), SKCM, TGCT, THCA, UCEC, and UCS. Here, YTHDC2 is linked to bladder transitional cell carcinoma.